Nymox Pharmaceutical Corporation reported earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported net loss of $1,362,840, or $0.04 per share compared to net loss of $1,318,293, or $0.04 per share for the same quarter a year ago. Net losses include stock compensation charges for the quarter of $322,808 in 2009 and $293,180 in 2008. The increase of the net loss for the quarter is mainly attributable to expenses relating to the launch of Phase 3 clinical trials for NX-1207. Product sales amounted to $71,904 compared to $82,171 for the same quarter a year ago. For the nine months, the company reported net loss of $3,587,251, or $0.12 per share compared to net loss of $3,714,188, or $0.13 per share for the nine months ending September 30, 2008. Net losses include stock compensation charges of $881,344 in 2009 and $702,540 in 2008. The decrease in net losses for the nine months period is attributable to reduced general and administrative expenditures compared to 2008. Product sales amounted to $248,471 compared to $306,849 for the same periods in 2008 due to a decrease in sales attributable to the current economic slowdown.

Nymox Pharmaceutical Corporation announced that a new formal statistical analysis of double-blind clinical trial data from pooled subjects in Phase 2 clinical trials for NX-1207, the Company's investigational treatment for BPH, confirmed that clinically significant benefits of a single NX-1207 treatment extend to 12 months or longer. The new analysis pooled the results from double-blind follow-up studies involving 159 men treated with a single injection of either placebo or NX-1207. A statistically significant difference in standardized BPH symptom score improvement at mean 13.5 months after a single treatment was found between NX-1207 2.5 mg (the therapeutic dose of NX-1207) and placebo. The median improvement in BPH Symptom Score in subjects given a single injection of NX-1207 at 12 months was 9.0 points (p less than 0.003). NX-1207 is currently being tested in Phase 3 clinical trials in centers across the U.S. This new data provides solid evidence accompanying and confirming earlier reports of a significant proportion of patients who received a single dose of NX-1207 and maintained their improvement in BPH symptoms for up to 5 years. Urologists in the U.S. have expressed very positive comments about the potential of NX-1207 to improve the care of millions of men with BPH. Completed clinical trials to date have shown that men treated with NX-1207 reported statistically significant improvement in BPH symptoms 3 months after a single NX-1207 treatment with no reported serious drug-related side effects, including no (0%) significant sexual side effects. In two multi-center Phase 2 U.S. prospective randomized blinded clinical trials, the aggregated mean improvement in the BPH symptom score for 2.5 mg NX-1207 was 10.3 points or a 44% improvement in BPH symptom score. By comparison, currently approved drugs for BPH provide on average 3 to 5 points improvement, must be taken daily to achieve or maintain benefit, and often have unwanted side effects such as impotence, loss of libido, retrograde ejaculation, dizziness, and weakness. NX-1207 involves a new targeted approach to the treatment of BPH. NX-1207 is injected by a urologist in an office setting directly into the zone of the prostate where the enlargement occurs. The entire procedure lasts on average 5-10 minutes, with the injection taking 1-2 minutes, does not require anesthesia or catheterization, and involves little or no pain or discomfort.

Nymox Pharmaceutical Corporation announced that NX-1207, the company's lead drug in development, has been shown to repeatedly produce strongly positive results when given to animals with hepatocellular carcinoma. In the experimental studies, the cancers were significantly reduced in size after 2 local injections of NX-1207. The rodents in the studies had transplanted human HCC, a standard model for cancer research. These animals had an average tumor burden reduction of close to 50% after 20 days. The NX-1207 used in these studies is a different formulation and a higher dosage from that of NX-1207 used to treat benign prostatic hyperplasia (BPH). The company intends to advance NX-1207 into human clinical trials for the treatment of HCC. There is a large unmet need for new treatments for HCC, the cause of about 90% of primary liver cancer cases in adults. Worldwide, primary liver cancer is the sixth most common cancer but because of very poor survival rates is the third cause of cancer-related deaths. NX-1207 is a novel drug developed by Nymox which is in Phase 3 development for the treatment of benign prostatic hyperplasia (BPH). The drug has been successful in a series of blinded controlled multi-center U.S. clinical trials where it has been found to produce improvements that are about double that reported for currently approved BPH drugs.